CIK 0001672619
- Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811523849
- Phone
- +1 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 20,000 shares at an average $26.75 ($535,099)
- 4 Planned sale Director sold 1,230 shares at an average $26.75 ($32,902)
- 4 Planned sale CHIEF OPERATING OFFICER sold 48,300 shares at an average $27.99 ($1,351,762)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 132,500 shares at an average $26.23 ($3,476,014)
- 4 Planned sale Director sold 13,920 shares at an average $25.02 ($348,281)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion CHIEF FINANCIAL OFFICER acquired 13,000 shares (option exercise)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 5,000 shares at $16.84 ($84,206)
- 4 Exercise or conversion Director acquired 15,958 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,663 shares at an average $21.02 ($140,073)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $22.33 ($279,155)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.82 ($272,739)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at an average $17.40 ($116,034)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at $22.08 ($276,025)
- 4 Planned sale PRESIDENT AND CEO sold 12,500 shares at $21.33 ($266,654)
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at $20.10 ($133,993)
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $20.40 ($66,291)
Page 3 of 20 · 383 filings